v3.26.1
Lessor Leases
6 Months Ended
Jun. 30, 2026
Leases [Abstract]  
Lessor Leases Lessor Leases
Sales-Type Leases
The Company enters into non-cancelable sales-type lease arrangements with the leases varying in length from one to ten years. The Company optimizes cash flows by selling a majority of its sales-type leases, other than those relating to U.S. government hospitals and SaaS and Expert Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, to third-party leasing finance companies on a non-recourse basis. The Company generally has no obligation to the leasing company once the lease has been sold.
The following table presents the Company’s income recognized from sales-type leases:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
(In thousands)
Sales-type lease revenues$3,814 $6,631 $10,114 $12,449 
Cost of sales-type lease revenues(2,347)(4,102)(6,120)(7,039)
Selling profit on sales-type lease revenues$1,467 $2,529 $3,994 $5,410 
The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components:
June 30,
2026
December 31,
2025
(In thousands)
Net minimum lease payments to be received$83,794 $88,372 
Less: Unearned interest income portion(12,441)(12,982)
Net investment in sales-type leases71,353 75,390 
Less: Current portion (1)
(14,848)(14,648)
Long-term investment in sales-type leases, net$56,505 $60,742 
_________________________________________________
(1)    The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.
The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value.
The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows:
June 30,
2026
(In thousands)
Remaining six months of 2026$9,065 
202717,612 
202817,311 
202914,662 
203010,286 
Thereafter14,858 
Total future minimum sales-type lease payments83,794 
Present value adjustment(12,441)
Total net investment in sales-type leases$71,353 
Lessor Leases Lessor Leases
Sales-Type Leases
The Company enters into non-cancelable sales-type lease arrangements with the leases varying in length from one to ten years. The Company optimizes cash flows by selling a majority of its sales-type leases, other than those relating to U.S. government hospitals and SaaS and Expert Services products, including Central Pharmacy Dispensing Service and IV Compounding Service, to third-party leasing finance companies on a non-recourse basis. The Company generally has no obligation to the leasing company once the lease has been sold.
The following table presents the Company’s income recognized from sales-type leases:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
(In thousands)
Sales-type lease revenues$3,814 $6,631 $10,114 $12,449 
Cost of sales-type lease revenues(2,347)(4,102)(6,120)(7,039)
Selling profit on sales-type lease revenues$1,467 $2,529 $3,994 $5,410 
The receivables as a result of these types of transactions are collateralized by the underlying equipment leased and consist of the following components:
June 30,
2026
December 31,
2025
(In thousands)
Net minimum lease payments to be received$83,794 $88,372 
Less: Unearned interest income portion(12,441)(12,982)
Net investment in sales-type leases71,353 75,390 
Less: Current portion (1)
(14,848)(14,648)
Long-term investment in sales-type leases, net$56,505 $60,742 
_________________________________________________
(1)    The current portion of the net investment in sales-type leases is included in other current assets in the Condensed Consolidated Balance Sheets.
The carrying amount of the Company’s sales-type lease receivables is a reasonable estimate of fair value.
The maturity schedule of future minimum lease payments under sales-type leases retained in-house and the reconciliation to the net investment in sales-type leases reported on the Condensed Consolidated Balance Sheets was as follows:
June 30,
2026
(In thousands)
Remaining six months of 2026$9,065 
202717,612 
202817,311 
202914,662 
203010,286 
Thereafter14,858 
Total future minimum sales-type lease payments83,794 
Present value adjustment(12,441)
Total net investment in sales-type leases$71,353